Clinical Trial Update: Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sorafenib in combination with paclitaxel for adrenocortical carcinoma, with the trial status listed as unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma

Drugs mentioned

• Paclitaxel (Taxol) (paclitaxel)
• Sorafenib (Nexavar) (Sorafenib)

Snippet

Sponsor: University of Turin, Italy | Conditions: Adrenocortical Carcinoma | Phase 2 | Status: UNKNOWN